CH 3 O-PEG-NH 2 (MW 550) and mono-protected di-amine terminated tert-butoxycarbonyl-NH-PEG- 
S 2 test. 30 ml cold ether was added to precipitate the crude product, which was then centrifuged at 0 C to remove supernatant to give an oil-to-wax-like residue. 5ml H 2 O was added to dissolve the residue and the solution was filtered through 0.45 m pore size membrane filter. Lyophilization of the filtrate gave the product as a pale-yellow wax.
1H NMR (CDCl 3 , 500 MHz) δ (ppm): 6.5~6.7 (m, 3H), 3.50~3.70 (bm, 56H), 2.81 (dd, 2H), 2.68 (dd, 2H) MS (M+1) + : average MW 692.6 2. Synthesis of biotin-PEG-NH 2 0.1 mmol (200mg) of tBoc-NH-PEG-NH 2 (average MW 1990.2) was dissolved in 500 l DMF and 0.2 mmol (42mg) biotin was dissolved separately in 500l dimethyl sulfoxide (DMSO). The two solutions were mixed, to which 0.2 mmol BOP, 0.2 mmol HOBT and 0.25 mmol DIPEA in 500 l DMF were added. The reaction mixture was stirred at room temperature for 12 hours. A negative ninhydrin test confirmed completion of the amide formation between (tBoc)NH-PEG-NH 2 and biotin. 30 ml cold ether was added to precipitate the crude product, and the mixture was centrifuged at 0 C to remove the supernatant and gave a waxy residue. Without further purification, deprotection of tBoc group on the crude product was carried out as follows. About 220 mg crude product (tBoc)NH-PEG-NH-biotin was dissolved in a mixture of 5 ml dichloromethane (DCM) and 5ml trifluoroacetic acid (TFA). The solution was stirred at room temperature for 2 hours and the solvent was evaporated under vacuum. 2ml TFA was added to dissolve the oily residue and 30 ml cold ether was added to precipitate the crude product.
Centrifugation of the mixture at 0 C gave a soft wax-like product. 5ml H 2 O was added to dissolve the residue and the solution was filtrated through a 0.45 m pore size membrane filter.
Lyophilization of the filtrate gave the product biotin-PEG-NH 2  TFA as a white, solid wax. mmol) HOBT and 25l IPEA was mixed in 1ml DMF and the mixture was added to the neutralized solution of compound 2. The final reaction mixture was stirred at room temperature for 16 hours. 20ml diethyl ether was added to precipitate the crude product and centrifugation of the mixture at 0 C gave a waxy residue. 10ml of a solution containing 50% DCM and 50%TFA was used to dissolve the residue and stirred at RT for 3 hours to remove the tBoc groups at the side chains of lysine on the PEG-peptide conjugate. The reaction mixture was concentrated under vacuum to about 2 ml and 25 ml cold ether was added. After centrifugation of the mixture at 0 C, crude product was obtained. 10 ml H 2 O was added to dissolve the residue and lyophilization of the solution gave the product compound 4 as white, solid wax/powder, which was further purified by RP-HPLC. dilute the DA-BTZ stock to 1 mM, and pH of such solutions were adjusted with 4N NaOH in D 2 O to 5.5, 6.5, 7.4 and 8.5. These solutions were analyzed an hour after preparation on AVANCE III 500 MHz and peak integrals in the range of 7.2 to 5.5 ppm were used for quantifying the degree of dissociation of DA-BTZ presented in Figure 2B . 9. Cell culture and biotin-mediated cell uptake of PEG-FITC MDA-MB-231 and MCF-7 breast cancer cells were originally purchased from ATCC and cultured in MEM containing 10 mM L-glutamine, nonessential amino acids, 10 mM HEPES, 100 U/ml streptomycin, 100 U/ ml penicillin and 10% FBS at 37C under 5% CO 2 . Passages between 9 and 12 were used for all the cell experiments in our work. MCF-10A-Vector and MCF-10A-H-RasV12 cells 1 were cultured in DMEM-F12 media supplemented with 20 ng/ml EGF, 10 g/ml insulin, 0.5g/ml hydrocortisone, 100 ng/ml cholera toxin, 100 U/ml streptomycin, 100 U/ ml penicillin and 5% FBS.
MALDI-TOF MS (M+1)
Cells were seeded in 24-well plates at a density of 110 
Preparation of catechol polymer-bortezomib conjugates for cytotoxicity assays
For all the experiments where polymer-bortezomib conjugates were tested, the following sample preparation method was used. Bortezomib and catechol polymers including PC and BPC were separately dissolved in DMSO at 0.1 M. Bortezomib-polymer conjugates were prepared by mixing solutions of 0.1M bortezomib and 0.1M PC or BPC in DMSO at volume ratio 4:1. These stock solutions were then diluted in PBS (containing Ca   2+ and Mg
2+
) to achieve a 0.1mM concentration of each compound, which were further diluted with the cell assay buffers (cell growth media containing 1% serum) to obtain final solutions used in cytotoxicity studies. shown in Figure 4C .
